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Background: Influenza and pneumonia combined are the leading causes of death due to infectious diseases in the
United States. We describe factors associated with pneumonia among adults hospitalized with influenza.
Methods: Through the Emerging Infections Program, we identified adults ≥ 18 years, who were hospitalized with
laboratory-confirmed influenza during October 2005 through April 2008, and had a chest radiograph (CXR) performed.
Pneumonia was defined as the presence of a CXR infiltrate and either an ICD-9-CM code or discharge summary
diagnosis of pneumonia.
Results: Among 4,765 adults hospitalized with influenza, 1392 (29 %) had pneumonia. In multivariable analysis,
factors associated with pneumonia included: age ≥ 75 years, adjusted odds ratio (AOR) 1.27 (95 % confidence
interval 1.10–1.46), white race AOR 1.24 (1.03–1.49), nursing home residence AOR 1.37 (1.14–1.66), chronic lung
disease AOR 1.37 (1.18–1.59), immunosuppression AOR 1.45 (1.19–1.78), and asthma AOR 0.76 (0.62–0.92). Patients
with pneumonia were significantly more likely to require intensive care unit (ICU) admission (27 % vs. 10 %),
mechanical ventilation (18 % vs. 5 %), and to die (9 % vs. 2 %).
Conclusions: Pneumonia was present in nearly one-third of adults hospitalized with influenza and was associated
with ICU admission and death. Among patients hospitalized with influenza, older patients and those with certain
underlying conditions are more likely to have pneumonia. Pneumonia is common among adults hospitalized with
influenza and should be evaluated and treated promptly.
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Influenza illness is generally characterized by acute onset
of fever, mylagias, and respiratory symptoms, and while
disease usually resolves without complications in healthy
indiviudals, influenza is associated with an annual in-
crease in hospital admissions for pulmonary, cardiovas-
cular and neuromuscular compliations [1–3]. The* Correspondence: izj7@cdc.gov
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article, unless otherwise stated.etiology of influenza-associated pneumonia may include
primary influenza pneumonia, secondary bacterial
pneumonia, or concomitant viral and bacterial pneumo-
nia [1, 4, 5]. Pulmonary complications of influenza, in-
cluding pneumonia and exacerbations of chronic
pulmonary disease, are common and result in significant
morbidity and mortality. Oliveira and colleagues found
that among all patients admitted to a large metropolitan
hospital with influenza during the 1999–2000 season,
49 % had pneumonia [6]. Further, in a study conducted
over 4 influenza seasons (1999–2003), Murata and col-
leagues found that among 193 patients hospitalized with
influenza A, 52 % had some type of acute findings onis distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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trates [7]. Although there is evidence that adult patients
with underlying cardiac or pulmonary disease are more
likely to develop influenza-associated pneumonia than
those without underlying medical conditions [6, 7], much
of the data describing factors associated with influenza-
associated pneumonia among adults comes from case
series conducted at single sites and during a limited num-
ber of seasons. Using data from a large multi-center, geo-
graphically diverse, population-based surveillance system,
we describe factors associated with pneumonia among
adults hospitalized with influenza over three consecutive
years in which seasonal influenza viruses circulated.
Methods
The Emerging Infections Program (EIP) network conducts
active population-based surveillance for laboratory-confirmed
influenza-associated hospitalizations. The network began
adult surveillance in 2005 and covers over 80 counties in
10 states (California, Colorado, Connecticut, Georgia,
Maryland, Minnesota, New Mexico, New York, Oregon,
and Tennessee), representing approximately 7 % of the
adult U.S. population [8]. Patients were included in EIP in-
fluenza surveillance if they resided and were hospitalized
in an EIP catchment area and were hospitalized within
14 days of a positive influenza diagnostic test result.
Patients were excluded if the first positive influenza speci-
men was obtained >3 days after hospital admission be-
cause these patients might have had healthcare-associated
influenza infection. Influenza testing was performed at the
discretion of health care providers. Medical charts of hos-
pitalized patients with laboratory-confirmed influenza
were retrospectively reviewed [8, 9].
The study period comprised 3 influenza seasons, 2005–
2006 to 2007–2008. Patients were included in this analysis
if they were ≥ 18 years of age, were hospitalized with
laboratory-confirmed influenza during the 2005–2006
through 2007–2008 influenza seasons, and had a chest
radiograph (CXR) performed during hospitalization. The
following data were collected on patients: demographics,
results of laboratory tests for influenza, influenza vaccin-
ation status for the current season, underlying medical
conditions, bacterial coinfections, CXR data, antiviral
treatment, clinical outcomes, and discharge diagnoses. La-
boratory confirmation of influenza was based on viral cul-
ture, direct or indirect immunoflourescence antibody
staining, reverse-transcription polymerase chain reaction,
or a rapid antigen test. Surveillance staff completed med-
ical record abstractions using check boxes to indicate
whether or not a new infiltrate or consolidation was re-
corded on the official CXR transcript. Discharge diagnoses
were captured in two ways: 1) the first nine international
classification of diseases (ICD-9-CM) codes for each case
were abstracted from the medical record; 2) check boxeswere marked for certain diagnoses, including pneumonia,
if they were recorded by clinicians on the discharge sum-
mary. Pneumonia was defined as the presence of a new in-
filtrate on CXR and either an ICD-9-CM discharge
diagnosis code for pneumonia (480–487.0) or a diagnosis
of pneumonia recorded on discharge summary.
Information on the presence of selected bacterial in-
fections was available only for patients who had a posi-
tive culture. A bacterial infection was recorded if
bacteria other than those that are commonly considered
to be contaminants grew from a sterile body site or a
non-sterile respiratory site culture obtained within 3 cal-
endar days of hospital admission. Sterile body sites for
bacterial infections included blood, pleural fluid, cere-
brospinal fluid, bronchoalveolar lavage fluid, and deep
tissue biopsy. Non-sterile respiratory sites included spu-
tum and endotracheal aspirates.
Use of influenza antiviral therapy was examined for all
individuals. Among those who were treated with anti-
viral agents, timing of treatment was assessed in relation
to hospitalization date. Early antiviral treatment was de-
fined as initiation of antiviral treatment within 2 days of
hospital admission.
We used bivariate analysis to compare adults hospital-
ized with influenza with and without pneumonia. We
used χ2 and Fisher exact tests for categorical variables
and t-tests and Wilcoxon-rank sum tests for continuous
and ordinal variables. All variables significant in bivariate
analysis, as well as biologically plausible variables, and
potential confounders were included in a multivariable
logistic regression model to identify factors independ-
ently associated with influenza-associated pneumonia.
We used the Breslow-Day test for homogeneity to assess
for effect modification of select variables. All tests were
two-tailed and a p-value of 0.05 was considered signifi-
cant. Analyses were conducted using SAS Version 9.2
(SAS Institute Inc., Cary, NC).Ethics statement EIP adult influenza hospitalization
surveillance activities during the 2005–2007 influenza
seasons were determined by the Centers for Disease
Control and Prevention (CDC) Institutional Review
Board (IRB) not to involve research in accordance with
the federal regulations for the protection of human sub-
jects in research. Starting with the 2007-2008 season,
research questions were added to evaluate factors associ-
ated with severe outcomes during hospitalizations, and
IRB review was conducted at all surveillance sites and
the CDC. The protocol was approved by the CDC IRB
and was either approved or received exempt status by all
surveillance site IRBs. Because all surveillance data was
analyzed anonymously, neither verbal nor written in-
formed consent was obtained from participants.
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Patient characteristics
During the study period, of 5055 adults hospitalized with
laboratory-confirmed influenza, 4765 (94.3 %) had an
available CXR report and discharge diagnosis informa-
tion and were therefore included in our study. Of the
4765 adults, 1392 (29 %) had pneumonia. The preva-
lence of pneumonia did not vary significantly over the 3
influenza seasons included in the analysis. Adults
≥75 years of age represented the age group with the
highest proportion of patients hospitalized with and
without influenza-associated pneumonia (Fig. 1). The
median age of patients with pneumonia compared with
patients without pneumonia was 74 years versus 69 years
(p <0.01) (Table 1). The majority of patients hospital-
ized with and without influenza-associated pneumonia
were white. White patients were older (median age
74 years) than black patients (53 years), Hispanic pa-
tients (56 years), and patients of other races including
Asian, Pacific Islander, American Indian, Alaskan Na-
tive, and multi-race (69 years) (p <0.01). Patients aged
65 years and above had a higher proportion of under-
lying conditions (90 %) compared to patients aged <
65 years (79 %) (p < 0.01). Influenza was diagnosed by
rapid test only in 1048/1390 (75 %) patients with pneu-
monia and in 2396/3368 (71 %) patients without pneu-
monia (p < 0.01).
The median number of days from symptom onset to
hospital admission was 2 days for patients with and
without pneumonia (Table 1). Patients with pneumonia
were significantly more likely than patients without
pneumonia to reside in a nursing home prior to hos-
pital admission, to have received influenza vaccine, and
to have the following underlying medical conditions:
chronic lung disease, cardiovascular disease, andFig. 1 Age distribution of adults hospitalized with laboratory-confirmed inf
2005–2008 (n=4765). Bar labels denote percent of adults in each age groupimmunosuppression. Patients with pneumonia were
significantly less likely than patients without pneumo-
nia to have asthma (Table 1). A description of the most
frequent discharge diagnoses (based on first listed ICD-
9 diagnosis code) among patients with and without
pneumonia can be found in Additional file 1: Table S1.
Except for influenza vaccination and cardiovascular
disease, all factors included in a multivariable model
remained independently associated with pneumonia in-
cluding age ≥75 years [adjusted odds ration (AOR)
1.27], white race (AOR 1.24), nursing home residence
(AOR 1.37) chronic lung disease (AOR 1.37), immuno-
suppression (AOR 1.45) and asthma (AOR 0.76)
(Table 1).
Outcomes
Sixty-one patients with pneumonia and 68 patients
without pneumonia had sterile site bacterial infec-
tions, 90 % of which were cultured from the blood
(Table 2). The most common pathogens cultured
from sterile sites in patients with pneumonia were
Staphylococcous aureus (S. aureus) and Streptococcus
pneumonia (S. pneumonia).
Patients with pneumonia had a longer median length of
hospital stay than patients without pneumonia (5 days ver-
sus 3 days; p <0.01). Patients with pneumonia were also
significantly more likely to have a hospital length of stay
greater than one week (AOR 2.99), require intensive care
unit (ICU) admission (AOR 3.62), require mechanical ven-
tilation (AOR 4.79), and die (AOR 6.06) (Table 3).
Among patients with pneumonia, factors independ-
ently associated with a poor outcome, defined as ICU
admission, need for mechanical ventilation or death, in-
cluded nursing home residence (AOR 1.6), chronic lung
disease (AOR 1.6), cardiovascular disease (AOR 1.4),luenza with and without pneumonia, Emerging Infections Program,
with pneumonia
Table 1 Comparison of characteristics of adults hospitalized with laboratory-confirmed influenza with and without pneumonia,
Emerging Infections Program, 2005–2008 (n = 4765)
Characteristic Patients with pneumonia;
n = 1392 no. (%)
Patients without pneumonia;





Age in years, median (range) 74 (18–101) 69 (18–102) --- ---
Age ≥75 years 663 (48) 1333 (40) 1.39 (1.23–1.58) 1.27 (1.10–1.46)
Male Sex 660 (47) 1430 (42) --- ---
Race/Ethnicity
White, non-Hispanic 900 (65) 2016 (60) 1.41 (1.18–1.69) 1.24 (1.03–1.49)
Black, non-Hispanic 204 (15) 642 (19) ref ref
Hispanic 67 (5) 180 (5) 1.18 (0.85–1.63) 1.13 (0.80–1.58)
Othera 48 (3) 115 (4) 1.32 (0.91–1.92) 1.26 (0.86–1.85)
Unknown 173 (12) 420 (12) --- ---
Virus Type
Influenza A 1037 (74) 2484 (74) 1.10 (0.95–1.28) ---
Influenza B 298 (21) 787 (23) ref ---
Unknown 57 (4) 98 (3) --- ---
Influenza Vaccineb
Yes 677 (49) 1586 (47) 1.20 (1.04–1.38) 1.00 (0.86–1.17)
No 438 (31) 1228 (36) ref ---
Unknown 265 (19) 536 (16) 1.39 (1.16–1.67) ---
Nursing Home Residentc 228 (16) 382 (11) 1.53 (1.28–1.83) 1.37 (1.14–1.66)
Underlying Conditionsd 1179 (85) 2855 (85) 1.01 (0.85–1.19) ---
Asthma 174 (13) 599 (18) 0.66 (0.55–0.76) 0.76 (0.62–0.92)
Chronic Lung Disease 417 (30) 787 (23) 1.40 (1.22–1.62) 1.37 (1.18–1.59)
Cardiovascular Disease 652 (47) 1462 (43) 1.15 (1.02–1.31) 0.99 (0.86–1.13)
Chronic Metabolic Disease 481 (35) 1161 (34) 1.01 (0.88–1.15) ---
Renal Disease 216 (15) 499 (15) 1.05 (0.88–1.25) ---
Immunosuppression 186 (13) 348 (10) 1.33 (1.09–1.61) 1.45 (1.19–1.78)
Cognitive Dysfunction 136 (10) 276 (8) 1.22 (0.98–1.51) ---
Neuromuscular Disease 79 (6) 168 (5) 1.15 (0.87–1.51) ---
Seizure Disorder 51 (4) 127 (4) 0.97 (0.69–1.36) ---
Cancer 52 (4) 118 (4) 1.07 (0.77–1.49) ---
Other Condition 67 (5) 165 (5) 0.98 (0.73–1.32) ---
Symptom onset to admission, median days
(range)e
2 (0–63) 2 (0–83) --- ---
aOther Races include Asian, Pacific Islander, American Indian, Alaskan Indian, and multi-race
bIncludes 4730 cases with non-missing data
cIncludes 4713 cases with non-missing data
dChronic lung disease: all diseases other than asthma, reactive airways disease and cystic fibrosis; Cardiovascular disease: structural cardiac defects, arrhythmias,
current ischemic heart disease, and congestive heart failure or other functional impairment; Chronic metabolic disease: diabetes, thyroid disorders, adrenal
insufficiency and pituitary abnormalities; Renal disease: chronic renal failure, nephrotic syndrome, renal tubular acidosis, glomerulonephritis, medullary cystic
disease, and polycystic kidney disease; Immunosuppression: HIV/AIDS, immunoglobulin deficiency, and immunosuppressive therapy; Cognitive dysfunction:
conditions where handling of respiratory secretions is impaired; Neuromuscular disease: muscular dystrophy, cerebral palsy, quadriplegia, spinal cord injury, and
spinal abnormalities, and stroke; Cancers: diagnosed within the past 12 months and exclude non-melanoma skin cancers, lymphoma, and leukemia; Other
conditions include pregnancy, hemoglobinopathy, lymphoma, leukemia, cystic fibrosis, Guillain Barré Syndrome
eIncludes 4404 cases with non-missing data
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1.5) (Table 4). Of note, older age was inversely associated
with a poor outcome (AOR 0.7) among patients hospi-
talized with pneumonia (Table 4).Treatment
Patients with pneumonia [823/1392 (59 %)] were signifi-
cantly more likely to receive influenza antiviral therapy than
patients without pneumonia [1815/3373 (54 %); P <0.01].
Table 2 Sterile sitea bacterial coinfections among adults
hospitalized with laboratory-confirmed influenza with and without
pneumonia, Emerging Infections Program, 2005–2008 (n = 129)
Pathogen Patients with
pneumonia
n = 61; no. (%)
Patients without
pneumonia
n = 68; no. (%)
Streptococcus pneumoniae 17 (28) 6 (9)
Group A streptococcus 4 (7) 3 (4)
Haemophilus influenzae 1 (2) 0
Neisseria meningitidis 1 (2) 0
Staphylococcus aureus 28 (46) 30 (44)
MRSA 15 14
MSSA 10 16
Unknown 3 (5) 0
Gram negative rodsb 3 (5) 10 (15)
Other streptococcic 4 (7) 8 (12)
Other pathogensd 2 (3) 5 (7)
Unknown pathogens 1 (2) 6 (9)
Information on the presence of select bacterial infections was available only
for patients who had a positive culture
aSterile site infections included the following: 118 (91 %) obtained from blood;
3 (2 %) obtained from CSF; 4 (3 %) obtained from pleural fluid; 4 (3 %)
obtained from biopsy tissue
bGram negative rods include: Escherichia coli, Acinetobacter baumanii,
Enterobacter cloacae, Klebsiella pneumoniae, Proteus mirabilis and
Pseudomonas aeruginosa
cOther streptococcus species include: agalactiae, group G streptococcus, oralis,
mitis, parasanguinis, salivarus, viridians group streptococci
dOther pathogens include: Aerococcus viridans, Enterococcus faecium,
Propionibacterium acnes, Clostridium perfringens, Corynebacterium striatum,
Staphylococcus hominis
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viral therapy, 98 % received oseltamivir. When limiting our
analysis to 2386 patients who presented to the hospital
within 2 days of symptom onset, 456/687 (66 %) patients
with pneumonia and 1118/1697 (66 %) patients without
pneumonia received antiviral treatment (p = 0.82). Among
1574 people who presented to the hospital within 2 days of
symptom onset and who received antiviral treatment, data
was available on length of time from admission to start of
antiviral treatment for 1534 people. The majority, 1469/
1534 (96 %) received early antiviral treatment; 871 (57 %)
on the day of admission, 470 (31 %) within one day ofTable 3 Clinical course and outcomes among adults hospitalized w
Emerging Infections Program, 2005–2008 (n = 4765)
Outcome Patients with pneumonia
n = 1392; no. (%)
Patients with
n = 3373; no.
Length of stay >7 days 414 (30) 408 (12)
Intensive Care Unit 370 (27) 329 (10)
Mechanical ventilation 254 (18) 162 (5)
Death 120 (9) 55 (2)
aEach outcome is adjusted for age, nursing home residence, the presence of underadmission, and 128 (8 %) within two days of admission.
Among 445 people with pneumonia, 418 (94 %) received
early antiviral treatment and among 1089 people without
pneumonia 1051 (96 %) received early antiviral treatment
(p = 0.02).Discussion
Through this large, population-based surveillance sys-
tem, we found that pneumonia was present in almost
one-third of U.S. adults hospitalized with laboratory-
confirmed influenza over three consecutive years in
which seasonal influenza viruses circulated. Patients with
pneumonia were older and were more likely to have cer-
tain underlying medical conditions than patients without
pneumonia. Patients with pneumonia were also more
likely to have a prolonged hospital stay, be admitted to
an ICU, require mechanical ventilation for respiratory
failure, and die. While patients with pneumonia were
more likely to receive antiviral therapy than those
without pneumonia, treatment was more often delayed
among patients with pneumonia.
Similar to findings from smaller inter-pandemic stud-
ies [6, 7] pneumonia was common among adults hospi-
talized with influenza in this study. Among those
hospitalized with influenza, older adults and nursing home
residents were at significantly increased risk for having
influenza-associated pneumonia. Respiratory viruses in-
cluding influenza are a common etiology of pneumonia in
older adults, and several factors may contribute to the de-
velopment of severe lower respiratory tract disease in
these individuals, including decreased respiratory muscle
strength and lung compliance, and waning humoral and
cell-mediated immunity [10–12]. Additional risk factors for
lower respiratory tract disease among older nursing home
residents include immobility and swallowing difficulties
leading to aspiration [13]. Within closed settings such as
nursing homes, large outbreaks of influenza and its subse-
quent complications, including severe pneumonia, may
rapidly evolve and lead to significant morbidity and mortal-
ity [10, 14]. Influenza virus infection should thus be consid-
ered a potential cause of pneumonia in older individuals







3.06 (2.62–3.57) 2.99 (2.54–3.53)
3.34 (2.83–3.94) 3.62 (3.04–4.32)
4.38 (3.56–5.39) 4.79 (3.82–6.01)
5.69 (4.11–7.88) 6.06 (4.21–8.71)
lying medical conditions, and days from symptom onset to hospital admission
Table 4 Factors associated with poor outcomes among adults hospitalized with laboratory-confirmed influenza and pneumonia,
Emerging Infections Program, 2005–2008 (n = 1392)
Characteristic Patients without poor outcomesa
n = 950; no. (%)
Patients with poor outcomesa






≥75 years 472 (50) 191 (43) 0.8 (0.6–0.9) 0.7 (0.5–0.8)
<75 years 478 (50) 251 (57) Ref
Sex ---
Male 452 (48) 208 (47) 1.0 (0.8–1.2)
Female 498 (52) 234 (53) Ref
Race/Ethnicity ---
White, Non-Hispanic 603 (64) 297 (67) 1.1 (0.8–1.4)
Otherc 219 (23) 100 (23) Ref
Unknown 128 (13) 46 (10) 0.8 (0.5–1.2)
Virus Type ---
Influenza A 700 (74) 237 (76) 1.3 (1.0–1.7)
Influenza B 216 (23) 82 (19) Ref
Unknown 34 (4) 23 (5) 1.8 (1.0–3.2)
Nursing Home Resident* 139 (15) 89 (20) 1.5 (1.1–2.0) 1.6 (1.2–2.2)
Underlying Conditions* 784 (83) 395 (90) 1.8 (1.3–2.6) ---
Chronic Lung Disease* 250 (26) 167 (38) 1.7 (1.3–2.2) 1.6 (1.2–2.0)
Cardiovascular Disease* 413 (44) 239 (54) 1.5 (1.2–1.9) 1.4 (1.1–1.8)
Chronic Metabolic Disease* 298 (31) 183 (41) 1.5 (1.2–1.9) 1.3 (1.0–1.7)
Renal Disease* 123 (13) 93 (21) 1.8 (1.3–2.4) 1.5 (1.1–2.0)
Immunosuppression* 109 (11) 77 (17) 1.6 (1.2–2.2) 1.5 (1.1–2.1)
*P-value for bivariate association < 0.05
aPoor outcome defined as ICU admission, need for mechanical ventilation or death
bVariables included in adjusted model included age, nursing home residence, chronic lung disease, cardiovascular disease, chronic metabolic disease, renal
disease and immunosuppression
cOther Race/Ethnicities include Black, Hispanic, Asian, Pacific Islander, American Indian, Alaskan Indian, and multi-race
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agnosed and treated promptly. Influenza vaccination is the
most effective method to prevent influenza and its compli-
cations, and older adults, residents of nursing homes and
other long-term-care facilities, and adults with underlying
medical conditions should be considered high priority
groups for receipt of annual influenza vaccination [15].
Similar to earlier studies conducted during periods of
seasonal influenza virus circulation, patients with pneu-
monia in this study were more likely to have underlying
medical conditions including chronic lung disease and
heart disease [6, 7]. An unexpected finding was
that patients with asthma in our analysis were less likely
to have a diagnosis of pneumonia than patients without
pneumonia. Our study results contrast with EIP surveil-
lance data in hospitalized children <18 years of age which
has shown that children with influenza-associated pneumo-
nia were more likely to have asthma than those without
pneumonia [16]. Studies of the association between asthma
and seasonal influenza-associated pneumonia among adults
are lacking. A possible explanation for our finding isthat respiratory distress caused by influenza-associated
asthma exacerbation provided an alternate reason for
hospitalization in adult patients in the absence of
pneumonia. Biases in hospital admission practices based
on the presence of underlying conditions may have also
contributed to admission of asthmatic patients with a less
severe respiratory presentation compared to patients with-
out underlying medical conditions.
Invasive bacterial infections, especially due to S. aureus
and S. pneumoniae, were observed among patients with
influenza-associated pneumonia in this study as well as
other studies conducted during inter-pandemic [7] and
pandemic periods [17]. Among patients with pneumonia, S.
aureus was the most common organism cultured from
specimens collected from sterile sites. Influenza virus and
S. aureus co-infections are increasing [18–20] and have
been associated with particularly severe cases of
community-acquired pneumonia during periods of sea-
sonal influenza virus circulation [21]. In patients hospi-
talized with influenza, sterile site cultures should be
collected as early as possible for detection of bacterial
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most likely bacterial organisms should be considered
[22, 23]. In our study, S. pneumoniae was the only or-
ganism to be cultured from a sterile site more frequently
in patients with pneumonia that in patients without
pneumonia. In addition to annual influenza vaccination,
pneumococcal vaccine should be administered to adults
aged 18–64 years with certain health conditions and to
all persons aged ≥65 years [24].
Patients with influenza-associated pneumonia had a sig-
nificantly increased risk of ICU admission, respiratory fail-
ure requiring mechanical ventilation, and death compared
with patients without pneumonia. While case series con-
ducted during the 2009 H1N1 pandemic demonstrated el-
evated frequencies of ICU admission (36–58 %) [25, 26],
respiratory failure (10–67 %) [25, 27] and death (7–39 %)
[25–28] among patients hospitalized with pandemic
H1N1 influenza-associated pneumonia, limited data is
available on the association between seasonal influenza-
associated pneumonia and severe outcomes. In a small
case series of patients hospitalized with influenza during
the 1999–2000 season, 10 (58 %) of 17 patients with pneu-
monia were admitted to the ICU and 5 (29 %) patients
died [7]. In another observational study of patients hospi-
talized with influenza during 1999–2003, 16 (16 %) of 101
patients with acute pulmonary disease were admitted to
the ICU, 10 (10 %) required mechanical ventilation, and 6
(6 %) died [6]. While pneumonia and acute respiratory dis-
tress syndrome (ARDS) have been shown to account for a
majority of deaths associated with influenza virus infection
during pandemics [28], data is limited on the association
between seasonal influenza virus infection and death from
pneumonia or ARDS.
In our analysis, only 55 % of patients hospitalized with
laboratory-confirmed influenza received influenza antiviral
treatment. When limiting the analysis to patients who pre-
sented to the hospital within 2 days of symptom onset,
only 66 % of all patients received antiviral treatment; the
majority received antiviral treatment within 1 day of hos-
pital admission. Multiple studies have found early antiviral
treatment to be associated with a reduction in serious
influenza-associated outcomes including the development
of lower respiratory tract infections [29–31]. The Advisory
Committee on Immunization Practices recommends em-
piric influenza antiviral treatment for all adults with sus-
pected or confirmed influenza who are hospitalized, have
severe, complicated, or progressive illness, or are at high
risk for influenza-associated complications [32].
Several limitations to this study should be noted. Influ-
enza diagnostic testing was performed at the discretion
of treating clinicians at the various EIP hospital sites.
While all hospitalized patients who tested positive for in-
fluenza were included in surveillance, data is unavailable
for hospitalized patients who tested negative forinfluenza or who were not tested. Thus, these data may
not be representative of all individuals hospitalized with
influenza who may not have been tested or have labora-
tory confirmation of influenza virus infection. It is pos-
sible that patients included in surveillance were more
likely to be tested for influenza because they were more
severely ill; thus a higher proportion of patients exhibit-
ing pneumonia-like symptoms may have been tested for
influenza than patients presenting with other symptoms.
Furthermore, in our analysis, patients with pneumonia
were compared to patients without pneumonia but with a
wide array of other diagnoses. Clinican influenza testing
practices based on patient diagnoses at presentation may
have biased our findings. In one study conducted in an
emergency department in Australia, patients presenting
with fever and respiratory diagnoses were more likely
to be tested for influenza than patients presenting with
cardiac or other diagnoses [33]. This study assessed
pneumonia specifically among adults hospitalized with
laboratory-confirmed influenza, including those whose in-
fluenza virus infection preceded hospitalization by more
than a few days, and findings are not generalizable to all
hospitalized individuals with pneumonia of other etiolo-
gies or to non-hospitalized individuals.
Several of the findings in this study may have been
biased by hospital admission practices. For example,
the finding of an inverse association between asthma
and pneumonia may have been due to more aggressive
admission of asthmatic patients presenting with respira-
tory distress despite the absence of pneumonia, compared
with patients without asthma. Biases related to hospital
admission practices were likely reduced by including pa-
tients from multiple hospital sites in geographically di-
verse settings. For certain underlying conditions such as
chronic lung disease and cardiovascular disease, disease
type and severity were not captured by the case report
form. Availability of detailed data on type and severity of
underlying conditions may have helped to better identify
factors more strongly associated with development of
influenza-associated pneumonia.
Radiographic data were based on review of CXR re-
ports by surveillance officers and not by actual review of
radiographs by a designated study radiologist. As a re-
sult, some individuals may have been misclassified as
having pneumonia based upon a report of infiltrates or
opacities, when in fact they had a more chronic pulmon-
ary condition or a transient episode of pulmonary edema
or effusion. There was no requirement regarding timing
of identification of radiologic abnormalities during the
hospitalization, and the timing of chest radiographs dur-
ing the hospitalization was not collected as part of EIP
surveillance; thus, some misclassification of community-
acquired pneumonia versus nosocomial pneumonia may
have occurred. Using ICD-9-CM code data may also
Garg et al. BMC Infectious Diseases  (2015) 15:369 Page 8 of 9have led to misclassification if a diagnosis code was
listed incorrectly or not listed at all. A joint case defin-
ition for pneumonia which used both radiographic data
and discharge diagnosis data from ICD-9-CM codes or
discharge summaries was utilized to minimize some of
these biases. Bacterial culture data was only available for
patients with a positive culture result rather than for all
specimens spent, thus limiting the interpretation of the
culture data.
Conclusions
Pneumonia is common among adults hospitalized with
seasonal influenza virus infection. Among patients hos-
pitalized with influenza, older adults and those with
underlying medical conditions may be more likely to
have pneumonia. Further studies are needed to explore
the association between influenza-associated pneumonia
and asthma in adults. Influenza-associated pneumonia
can lead to severe outcomes including ICU admission
and death. Adults hospitalized with suspected or con-
firmed influenza should receive early antiviral therapy,
prompt evaluation for pneumonia, and appropriate man-
agement upon diagnosis of pneumonia.Additional file
Additional file 1: Table S1. The 10 most frequent ICD-9 diagnosis
categories based on first ICD-9 code listed among adults hospitalized with
laboratory-confirmed influenza with and without pneumonia (n=4177).
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